Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSIBBBOOST: Osimertinib + Febuxostat in EGFR-mutated NSCLC
NCT07485452Phase 2Recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Jun 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of febuxostat in non-small cell lung cancer (NSCLC), sponsored by Maastricht University Medical Center+. Started Jun 2026; status: recruiting.
02
Drugs
febuxostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07485452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07485452.